Affiliation: University of Chicago
- Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphismL Iyer
Department of Human Genetics, Cancer Research Center, University of Chicago, IL 60637, USA
Clin Pharmacol Ther 65:576-82. 1999..The presence of an additional TA repeat [(TA)7TAA] in the TATA sequence of UGT1A1 has been associated with Gilbert's syndrome...
- Inherited variations in drug-metabolizing enzymes: significance in clinical oncologyL Iyer
Department of Medicine and Committee on Clinical Pharmacology, The University of Chicago, Chicago, Illinois 60637, USA
Mol Diagn 4:327-33. 1999....
- UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicityL Iyer
Department of Medicine, The University of Chicago, IL, USA
Pharmacogenomics J 2:43-7. 2002..The results suggest that screening for UGT1A1*28 polymorphism may identify patients with lower SN-38 glucuronidation rates and greater susceptibility to irinotecan induced gastrointestinal and bone marrow toxicity...
- Phase I clinical and pharmacogenetic study of weekly TAS-103 in patients with advanced cancerR B Ewesuedo
Committee on Clinical Pharmacology, Section of Pediatric Hematology-Oncology, Department of Pediatrics, University of Chicago, IL 60637, USA
J Clin Oncol 19:2084-90. 2001..Further studies to characterize the pharmacodynamics and pharmacogenetics of TAS-103 are warranted...
- Pharmacogenetics of anticancer agents: lessons from amonafide and irinotecanF Innocenti
Committee on Clinical Pharmacology, The University of Chicago, Illinois 60637, USA
Drug Metab Dispos 29:596-600. 2001..A clinical trial at the University of Chicago is ongoing to demonstrate the predictive significance of UGT1A1 genotyping for irinotecan pharmacodynamics...
- Epirubicin glucuronidation is catalyzed by human UDP-glucuronosyltransferase 2B7F Innocenti
The University of Chicago, Department of Medicine, Chicago, IL 60637, USA
Drug Metab Dispos 29:686-92. 2001..The reported tyrosine to histidine polymorphism in UGT2B7 does not alter the formation rate of epirubicin glucuronide, and undiscovered genetic polymorphisms in UGT2B7 might change the metabolic fate of this important anticancer agent...